Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients in control vs intervention arm

From: Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether–lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial

ParametersControl armb
(N = 141)
Intervention armb
(N = 139)
Sex, n (%) female65 (46.0)59 (42.5)
Age (years), median (IQR)10 (5–17)10 (5–14)
Age groups
 < 5 years, n (%)48 (34.0)35 (25.2)
 5–14 years, n (%)49 (34.8)71 (51.1)
 ≥ 15 years, n (%)44 (31.2)33 (23.7)
Weight (kg), median (IQR)26 (16.5–49.5)27 (18–43)
Screening P. falciparum parasitaemia (p/µL), geometric mean (95% CI)13,355 (9762–18,272)16,986 (12,936–22,305)
Enrollment P. falciparum parasitaemia (p/µL), geometric mean (95% CI)a15,744 (10,949–2263)16,561 (11,812–23,219)
Patients with P. falciparum gametocytaemia, n (%)3 (2.1)1 (0.7)
Haemoglobin (g/dL), median (IQR)12.2 (10.6–13.3)12.0 (10.7–13.1)
Fever (axillary temperature ≥ 37.5 °C), n (%)109 (77.3)110 (79.1)
Axillary temperature (°C), median (IQR)38.4 (37.6–39.0)38.2 (37.7–39.1)
  1. IQR inter-quartile range
  2. aEnrollment parasitaemia was determined about 1–2 h from completion of screening just before the first dose
  3. bControl arm received standard treatment with artemether–lumefantrine for 3 days and intervention arm received extended treatment with artemether–lumefantrine for 6 days with single low-dose primaquine